Catestatin: A multifunctional peptide from chromogranin A

Regulatory Peptides

Volumn 162, Issue 1-3, 2010, Pages 33-43

  Mahata, Sushil K ^a   Mahata, Manjula ^a   Fung, Maple M ^a   O'Connor, Daniel T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Baroreflex sensitivity; Blood pressure; Chemotaxis; Chromaffin; Chromogranin; Innate immunity; Myocardial contractility; Nicotine

Indexed keywords

CALCIUM ION; CATECHOLAMINE; CATESTATIN; CHROMOGRANIN A; NICOTINIC RECEPTOR; SODIUM ION;

ADRENAL GLAND; AMINO ACID SEQUENCE; AUTONOMIC NERVOUS SYSTEM FUNCTION; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR SYSTEM; CATECHOLAMINE RELEASE; CHEMOTAXIS; DESENSITIZATION; DOSE RESPONSE; DRUG MECHANISM; GENE LOCUS; HISTAMINE RELEASE; HUMAN; HYPERTENSION; INHIBITION KINETICS; INNATE IMMUNITY; KNOCKOUT MOUSE; MAST CELL; NONHUMAN; PATHOPHYSIOLOGY; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; VASODILATATION;

AMINO ACID SEQUENCE; ANIMALS; CHEMOTAXIS; CHROMOGRANIN A; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION;

BOVINAE; MUS; RATTUS; RODENTIA;

EID: 77952674867     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2010.01.006     Document Type: Review

References (105)

1. Winkler H., Fischer-Colbrie R. The chromogranins A and B: the first 25years and future perspectives. Neuroscience 1992, 49:497-528.
2. Taupenot L., Harper K.L., O'Connor D.T. Mechanisms of disease: the chromogranin-secretogranin family. New Engl J Med 2003, 348:1134-1149.
3. Helle K.B., Corti A., Metz-Boutigue M.H., Tota B. The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell Mol Life Sci 2007.
4. Montero-Hadjadje M., Vaingankar S., Elias S., Tostivint H., Mahata S.K., Anouar Y. Chromogranins A and B and secretogranin II: evolutionary and functional aspects. Acta Physiol (Oxf) 2008, 192:309-324.
5. Takiyyuddin M.A., Cervenka J.H., Hsiao R.J., Barbosa J.A., Parmer R.J., O'Connor D.T. Chromogranin A. Storage and release in hypertension. Hypertension 1990, 15:237-246.
6. Takiyyuddin M.A., Cervenka J.H., Sullivan P.A., Pandian M.R., Parmer R.J., Barbosa J.A., O'Connor D.T. Is physiologic sympathoadrenal catecholamine release exocytotic in humans?. Circulation 1990, 81:185-195.
7. Kim T., Tao-Cheng J., Eiden L.E., Loh Y.P. Chromogranin A, an "On/Off" switch controlling dense-core secretory granule biogenesis. Cell 2001, 106:499-509.
8. Simon J.P., Aunis D. Biochemistry of the chromogranin A protein family. Biochem J 1989, 262:1-13.
9. Huttner W.B., Gerdes H.H., Rosa P. The granin (chromogranin/secretogranin) family. Trends Biochem Sci 1991, 16:27-30.
10. O'Connor D.T. Chromogranin: widespread immunoreactivity in polypeptide hormone producing tissues and in serum. Regul Pept 1983, 6:263-280.
11. Iacangelo A., Affolter H.U., Eiden L.E., Herbert E., Grimes M. Bovine chromogranin A sequence and distribution of its messenger RNA in endocrine tissues. Nature 1986, 323:82-86.
12. Benedum U.M., Baeuerle P.A., Konecki D.S., Frank R., Powell J., Mallet J., Huttner W.B. The primary structure of bovine chromogranin A: a representative of a class of acidic secretory proteins common to a variety of peptidergic cells. Embo J 1986, 5:1495-1502.
13. Konecki D.S., Benedum U.M., Gerdes H.H., Huttner W.B. The primary structure of human chromogranin A and pancreastatin. J Biol Chem 1987, 262:17026-17030.
14. Wu H.J., Rozansky D.J., Parmer R.J., Gill B.M., O'Connor D.T. Structure and function of the chromogranin A gene. Clues to evolution and tissue-specific expression. J Biol Chem 1991, 266:13130-13134.
15. Rozansky D.J., Wu H., Tang K., Parmer R.J., O'Connor D.T. Glucocorticoid activation of chromogranin A gene expression. Identification and characterization of a novel glucocorticoid response element. J Clin Invest 1994, 94:2357-2368.
16. Tatemoto K., Efendic S., Mutt V., Makk G., Feistner G.J., Barchas J.D. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature 1986, 324:476-478.
17. O'Connor D.T., Cadman P.E., Smiley C., Salem R.M., Rao F., Smith J., Funk S.D., Mahata S.K., Mahata M., Wen G., Taupenot L., Gonzalez-Yanes C., Harper K.L., Henry R.R., Sanchez-Margalet V. Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism. J Clin Endocrinol Metab 2005, 90:5414-5425.
18. Gayen J.R., Saberi M., Schenk S., Biswas N., Vaingankar S.M., Cheung W.W., Najjar S.M., O'Connor D.T., Bandyopadhyay G., Mahata S.K. A novel pathway of insulin sensitivity in chromogranin a null mice: a crucial role for pancreastatin in glucose homeostasis. J Biol Chem 2009, 284:28498-28509.
19. Strub J.M., Goumon Y., Lugardon K., Capon C., Lopez M., Moniatte M., Van Dorsselaer A., Aunis D., Metz-Boutigue M.H. Antibacterial activity of glycosylated and phosphorylated chromogranin A-derived peptide 173-194 from bovine adrenal medullary chromaffin granules. J Biol Chem 1996, 271:28533-28540.
20. Aardal S., Helle K.B., Elsayed S., Reed R.K., Serck-Hanssen G. Vasostatins, comprising the N-terminal domain of chromogranin A, suppress tension in isolated human blood vessel segments. J Neuroendocrinol 1993, 5:405-412.
21. Mahata S.K., O'Connor D.T., Mahata M., Yoo S.H., Taupenot L., Wu H., Gill B.M., Parmer R.J. Novel autocrine feedback control of catecholamine release. A discrete chromogranin A fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 1997, 100:1623-1633.
22. 344-364) acts at the receptor to prevent nicotinic cholinergic tolerance. J Biol Chem 1999, 274:2920-2928.
23. Schober M., Howe P.R., Sperk G., Fischer-Colbrie R., Winkler H. An increased pool of secretory hormones and peptides in adrenal medulla of stroke-prone spontaneously hypertensive rats. Hypertension 1989, 13:469-474.
24. O'Connor D.T., Takiyyuddin M.A., Printz M.P., Dinh T.Q., Barbosa J.A., Rozansky D.J., Mahata S.K., Wu H., Kennedy B.P., Ziegler M.G., Wright F.A., Schlager G., Parmer R.J. Catecholamine storage vesicle protein expression in genetic hypertension. Blood Press 1999, 8:285-295.
25. Takiyyuddin M.A., De Nicola L., Gabbai F.B., Dinh T.Q., Kennedy B., Ziegler M.G., Sabban E.L., Parmer R.J., O'Connor D.T. Catecholamine secretory vesicles. Augmented chromogranins and amines in secondary hypertension. Hypertension 1993, 21:674-679.
26. Takiyyuddin M.A., Parmer R.J., Kailasam M.T., Cervenka J.H., Kennedy B., Ziegler M.G., Lin M.C., Li J., Grim C.E., Wright F.A., et al. Chromogranin A in human hypertension. Influence of heredity. Hypertension 1995, 26:213-220.
27. O'Connor D.T., Zhu G., Rao F., Taupenot L., Fung M.M., Das M., Mahata S.K., Mahata M., Wang L., Zhang K., Greenwood T.A., Shih P.A., Cockburn M.G., Ziegler M.G., Stridsberg M., Martin N.G., Whitfield J.B. Heritability and genome-wide linkage in US and Australian twins identify novel genomic regions controlling chromogranin a: implications for secretion and blood pressure. Circulation 2008, 118:247-257.
28. O'Connor D.T., Frigon R.P., Sokoloff R.L. Human chromogranin A. Purification and characterization from catecholamine storage vesicles of human pheochromocytoma. Hypertension 1984, 6:2-12.
29. Kimura N., Miura W., Noshiro T., Mizunashi K., Hanew K., Shimizu K., Watanabe T., Shibukawa S., Sohn H.E., Abe K., Miura Y., Nagura H. Plasma chromogranin A in pheochromocytoma, primary hyperparathyroidism and pituitary adenoma in comparison with catecholamine, parathyroid hormone and pituitary hormones. Endocr J 1997, 44:319-327.
30. Stridsberg M., Husebye E.S. Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma. Eur J Endocrinol 1997, 136:67-73.
31. O'Connor D.T., Deftos L.J. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 1986, 314:1145-1151.
32. Syversen U., Mignon M., Bonfils S., Kristensen A., Waldum H.L. Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients. Acta Oncol 1993, 32:161-165.
33. Nikou G.C., Lygidakis N.J., Toubanakis C., Pavlatos S., Tseleni-Balafouta S., Giannatou E., Mallas E., Safioleas M. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues. Hepatogastroenterology 2005, 52:731-741.
34. Ceconi C., Ferrari R., Bachetti T., Opasich C., Volterrani M., Colombo B., Parrinello G., Corti A. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J 2002, 23:967-974.
35. Omland T., Dickstein K., Syversen U. Association between plasma chromogranin A concentration and long-term mortality after myocardial infarction. Am J Med 2003, 114:25-30.
36. Pieroni M., Corti A., Tota B., Curnis F., Angelone T., Colombo B., Cerra M.C., Bellocci F., Crea F., Maseri A. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J 2007, 28:1117-1127.
37. Estensen M.E., Hognestad A., Syversen U., Squire I., Ng L., Kjekshus J., Dickstein K., Omland T. Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. Am Heart J 2006, 152(927):e1-e6.
38. Jansson A.M., Rosjo H., Omland T., Karlsson T., Hartford M., Flyvbjerg A., Caidahl K. Prognostic value of circulating chromogranin A levels in acute coronary syndromes. Eur Heart J 2009, 30:25-32.
39. Zhang D., Shooshtarizadeh P., Laventie B.J., Colin D.A., Chich J.F., Vidic J., de Barry J., Chasserot-Golaz S., Delalande F., Van Dorsselaer A., Schneider F., Helle K., Aunis D., Prevost G., Metz-Boutigue M.H. Two chromogranin a-derived peptides induce calcium entry in human neutrophils by calmodulin-regulated calcium independent phospholipase A2. PLoS ONE 2009, 4:e4501.
40. Zhang D., Lavaux T., Sapin R., Lavigne T., Castelain V., Aunis D., Metz-Boutigue M.H., Schneider F. Serum concentration of chromogranin A at admission: an early biomarker of severity in critically ill patients. Ann Med 2009, 41:38-44.
41. Zhang D., Lavaux T., Voegeli A.C., Lavigne T., Castelain V., Meyer N., Sapin R., Aunis D., Metz-Boutigue M.H., Schneider F. Prognostic value of chromogranin A at admission in critically ill patients: a cohort study in a medical intensive care unit. Clin Chem 2008, 54:1497-1503.
42. O'Connor D.T., Kailasam M.T., Kennedy B.P., Ziegler M.G., Yanaihara N., Parmer R.J. Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens 2002, 20:1335-1345.
43. Mahapatra N.R., O'Connor D.T., Vaingankar S.M., Sinha Hikim A.P., Mahata M., Ray S., Staite E., Wu H., Gu Y., Dalton N., Kennedy B.P., Ziegler M.G., Ross J., Mahata S.K. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest 2005, 115:1942-1952.
44. Kennedy B.P., Mahata S.K., O'Connor D.T., Ziegler M.G. Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo. Peptides 1998, 19:1241-1248.
45. MM Fung, RM Salem, P Mehtani, B Thomas, CF Lu, B Perez, F Rao, M Stridsberg, M Ziegler, SK Mahata, DT. OC. Direct vasoactive effects of the chromogranin A (CHGA) peptide catestatin in humans in vivo. Clin Exp Hypertens in press.
46. Angelone T., Quintieri A.M., Brar B.K., Limchaiyawat P.T., Tota B., Mahata S.K., Cerra M.C. The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology 2008, 149:4780-4793.
47. Gayen J.R., Gu Y., O'Connor D.T., Mahata S.K. Global disturbances in autonomic function yield cardiovascular instability and hypertension in the chromogranin A null mouse. Endocrinology 2009, 150:5027-5035.
48. Egger M., Beer A.G., Theurl M., Schgoer W., Hotter B., Tatarczyk T., Vasiljevic D., Frauscher S., Marksteiner J., Patsch J.R., Schratzberger P., Djanani A.M., Mahata S.K., Kirchmair R. Monocyte migration: a novel effect and signaling pathways of catestatin. Eur J Pharmacol 2008, 598:104-111.
49. Briolat J., Wu S.D., Mahata S.K., Gonthier B., Bagnard D., Chasserot-Golaz S., Helle K.B., Aunis D., Metz-Boutigue M.H. New antimicrobial activity for the catecholamine release-inhibitory peptide from chromogranin A. Cell Mol Life Sci 2005, 62:377-385.
50. Radek K.A., Lopez-Garcia B., Hupe M., Niesman I.R., Elias P.M., Taupenot L., Mahata S.K., O'Connor D.T., Gallo R.L. The neuroendocrine peptide catestatin is a cutaneous antimicrobial and induced in the skin after injury. J Invest Dermatol 2008, 128:1525-1534.
51. Simon J.P., Bader M.F., Aunis D. Secretion from chromaffin cells is controlled by chromogranin A-derived peptides. Proc Natl Acad Sci U S A 1988, 85:1712-1716.
52. Rao F., Wen G., Gayen J.R., Das M., Vaingankar S.M., Rana B.K., Mahata M., Kennedy B.P., Salem R.M., Stridsberg M., Abel K., Smith D.W., Eskin E., Schork N.J., Hamilton B.A., Ziegler M.G., Mahata S.K., O'Connor D.T. Catecholamine release-inhibitory peptide catestatin (chromogranin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation 2007, 115:2271-2281.
53. Taylor C.V., Taupenot L., Mahata S.K., Mahata M., Wu H., Yasothornsrikul S., Toneff T., Caporale C., Jiang Q., Parmer R.J., Hook V.Y., O'Connor D.T. Formation of the catecholamine release-inhibitory peptide catestatin from chromogranin A. Determination of proteolytic cleavage sites in hormone storage granules. J Biol Chem 2000, 275:22905-22915.
54. Benjannet S., Rondeau N., Day R., Chretien M., Seidah N.G. PC1 and PC2 are proprotein convertases capable of cleaving proopiomelanocortin at distinct pairs of basic residues. Proc Natl Acad Sci U S A 1991, 88:3564-3568.
55. Dhanvantari S., Seidah N.G., Brubaker P.L. Role of prohormone convertases in the tissue-specific processing of proglucagon. Mol Endocrinol 1996, 10:342-355.
56. Azaryan A.V., Krieger T.J., Hook V.Y. Purification and characteristics of the candidate prohormone processing proteases PC2 and PC1/3 from bovine adrenal medulla chromaffin granules. J Biol Chem 1995, 270:8201-8208.
57. Lee J.C., Taylor C.V., Gaucher S.P., Toneff T., Taupenot L., Yasothornsrikul S., Mahata S.K., Sei C., Parmer R.J., Neveu J.M., Lane W.S., Gibson B.W., O'Connor D.T., Hook V.Y. Primary sequence characterization of catestatin intermediates and peptides defines proteolytic cleavage sites utilized for converting chromogranin a into active catestatin secreted from neuroendocrine chromaffin cells. Biochemistry 2003, 42:6938-6946.
58. Parmer R.J., Mahata M., Gong Y., Mahata S.K., Jiang Q., O'Connor D.T., Xi X.-P., Miles L.A. Processing of chromogranin A by plasmin provides a novel mechanism for regulating catecholamine secretion. J Clin Invest 2000, 106:907-915.
59. Jiang Q., Taupenot L., Mahata S.K., Mahata M., O'Connor D.T., Miles L.A., Parmer R.J. Proteolytic cleavage of chromogranin A (CgA) by plasmin: selective liberation of a specific bioactive CgA fragment that regulates catecholamine release. J Biol Chem 2001, 276:25022-25029.
60. Biswas N., Vaingankar S.M., Mahata M., Das M., Gayen J.R., Taupenot L., Torpey J.W., O'Connor D.T., Mahata S.K. Proteolytic cleavage of human chromogranin a containing naturally occurring catestatin variants: differential processing at catestatin region by plasmin. Endocrinology 2008, 149:749-757.
61. Hook V., Yasothornsrikul S., Greenbaum D., Medzihradszky K.F., Troutner K., Toneff T., Bundey R., Logrinova A., Reinheckel T., Peters C., Bogyo M. Cathepsin L and Arg/Lys aminopeptidase: a distinct prohormone processing pathway for the biosynthesis of peptide neurotransmitters and hormones. Biol Chem 2004, 385:473-480.
62. Hwang S.R., Garza C., Mosier C., Toneff T., Wunderlich E., Goldsmith P., Hook V. Cathepsin L expression is directed to secretory vesicles for enkephalin neuropeptide biosynthesis and secretion. J Biol Chem 2007, 282:9556-9563.
63. Yasothornsrikul S., Greenbaum D., Medzihradszky K.F., Toneff T., Bundey R., Miller R., Schilling B., Petermann I., Dehnert J., Logvinova A., Goldsmith P., Neveu J.M., Lane W.S., Gibson B., Reinheckel T., Peters C., Bogyo M., Hook V. Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter. Proc Natl Acad Sci U S A 2003, 100:9590-9595.
64. Biswas N., Rodriguez-Flores J.L., Courel M., Gayen J.R., Vaingankar S.M., Mahata M., Torpey J.W., Taupenot L., O'Connor D.T., Mahata S.K. Cathepsin L co-localizes with chromogranin a in chromaffin vesicles to generate active peptides. Endocrinology 2009, 150:3547-3557.
65. Mahata S.K., Mahata M., Wu H., Parmer R.J., O'Connor D.T. Neurotrophin activation of catecholamine storage vesicle protein gene expression: signaling to chromogranin A biosynthesis. Neuroscience 1999, 88:405-424.
66. Livett B.G., Boksa P., Dean D.M., Mizobe F., Lindenbaum M.H. Use of isolated chromaffin cells to study basic release mechanisms. J Auton Nerv Syst 1983, 7:59-86.
67. De A., Krueger J.M., Simasko S.M. Tumor necrosis factor alpha increases cytosolic calcium responses to AMPA and KCl in primary cultures of rat hippocampal neurons. Brain Res 2003, 981:133-142.
68. Herrero C.J., Ales E., Pintado A.J., Lopez M.G., Garcia-Palomero E., Mahata S.K., O'Connor D.T., Garcia A.G., Montiel C. Modulatory mechanism of the endogenous peptide catestatin on neuronal nicotinic acetylcholine receptors and exocytosis. J Neurosci 2002, 22:377-388.
69. Mahata S.K., Mahata M., Wakade A.R., O'Connor D.T. Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A344-364): identification of amino acid residues crucial for activity. Mol Endocrinol 2000, 14:1525-1535.
70. Tsigelny I., Mahata S.K., Taupenot L., Preece N.E., Mahata M., Khan I., Parmer R.J., O'Connor D.T. Mechanism of action of chromogranin A on catecholamine release: molecular modeling of the catestatin region reveals a β-strand/loop/β-strand structure secured by hydrophobic interactions and predictive of activity. Regul Peptides 1998, 77:43-53.
71. Preece N.E., Nguyen M., Mahata M., Mahata S.K., Mahapatra N.R., Tsigelny I., O'Connor D.T. Conformational preferences and activities of peptides from the catecholamine release-inhibitory (catestatin) region of chromogranin A. Regul Pept 2004, 118:75-87.
72. Wen G., Mahata S.K., Cadman P., Mahata M., Ghosh S., Mahapatra N.R., Rao F., Stridsberg M., Smith D.W., Mahboubi P., Schork N.J., O'Connor D.T., Hamilton B.A. Both rare and common polymorphisms contribute functional variation at CHGA, a regulator of catecholamine physiology. Am J Hum Genet 2004, 74:197-207.
73. Mahata S.K., Mahata M., Wen G., Wong W.B., Mahapatra N.R., Hamilton B.A., O'Connor D.T. The catecholamine release-inhibitory "catestatin" fragment of chromogranin A: naturally occurring human variants with different potencies for multiple chromaffin cell nicotinic cholinergic responses. Mol Pharmacol 2004, 66:1180-1191.
74. Taupenot L., Mahata S.K., Wu H., O'Connor D.T. Peptidergic activation of transcription and secretion in chromaffin cells. Cis and trans signaling determinants of pituitary adenylyl cyclase-activating polypeptide (PACAP). J Clin Invest 1998, 101:863-876.
75. Wakade A.R. Studies on secretion of catecholamines evoked by acetylcholine or transmural stimulation of the rat adrenal gland. J Physiol 1981, 313:463-480.
76. Wakade T.D., Blank M.A., Malhotra R.K., Pourcho R., Wakade A.R. The peptide VIP is a neurotransmitter in rat adrenal medulla: physiological role in controlling catecholamine secretion. J Physiol 1991, 444:349-362.
77. Guo X., Wakade A.R. Differential secretion of catecholamines in response to peptidergic and cholinergic transmitters in rat adrenals. J Physiol (Lond) 1994, 475:539-545.
78. Wakade A.R., Wakade T.D. Contribution of nicotinic and muscarinic receptors in the secretion of catecholamines evoked by endogenous and exogenous acetylcholine. Neuroscience 1983, 10:973-978.
79. Mahata S.K., Mahapatra N.R., Mahata M., Wang T.C., Kennedy B.P., Ziegler M.G., O'Connor D.T. Catecholamine secretory vesicle stimulus-transcription coupling in vivo. Demonstration by a novel transgenic promoter/photoprotein reporter and inhibition of secretion and transcription by the chromogranin A fragment catestatin. J Biol Chem 2003, 278:32058-32067.
80. Tang K., Wu H., Mahata S.K., Taupenot L., Rozansky D.J., Parmer R.J., O'Connor D.T. Stimulus-transcription coupling in pheochromocytoma cells. Promoter region-specific activation of chromogranin A biosynthesis. J Biol Chem 1996, 271:28382-28390.
81. Tang K., Wu H., Mahata S.K., Mahata M., Gill B.M., Parmer R.J., O'Connor D.T. Stimulus coupling to transcription versus secretion in pheochromocytoma cells. Convergent and divergent signal transduction pathways and the crucial roles for route of cytosolic calcium entry and protein kinase C. J Clin Invest 1997, 100:1180-1192.
82. Kruger P.G., Mahata S.K., Helle K.B. Catestatin (CgA344-364) stimulates rat mast cell release of histamine in a manner comparable to mastoparan and other cationic charged neuropeptides. Regul Pept 2003, 114:29-35.
83. Munoz D.G. Chromogranin A-like immunoreactive neurites are major constituents of senile plaques. Lab Invest 1991, 64:826-832.
84. Rangon C.M., Haik S., Faucheux B.A., Metz-Boutigue M.H., Fierville F., Fuchs J.P., Hauw J.J., Aunis D. Different chromogranin immunoreactivity between prion and a-beta amyloid plaque. NeuroReport 2003, 14:755-758.
85. Taupenot L., Ciesielski-Treska J., Ulrich G., Chasserot-Golaz S., Aunis D., Bader M.F. Chromogranin A triggers a phenotypic transformation and the generation of nitric oxide in brain microglial cells. Neuroscience 1996, 72:377-389.
86. Ciesielski-Treska J., Ulrich G., Taupenot L., Chasserot-Golaz S., Corti A., Aunis D., Bader M.F. Chromogranin A induces a neurotoxic phenotype in brain microglial cells. J Biol Chem 1998, 273:14339-14346.
87. Lechner T., Adlassnig C., Humpel C., Kaufmann W.A., Maier H., Reinstadler-Kramer K., Hinterholzl J., Mahata S.K., Jellinger K.A., Marksteiner J. Chromogranin peptides in Alzheimer's disease. Exp Gerontol 2004, 39:101-113.
88. Lugardon K., Raffner R., Goumon Y., Corti A., Delmas A., Bulet P., Aunis D., Metz-Boutigue M.H. Antibacterial and antifungal activities of vasostatin-1, the N-terminal fragment of chromogranin A. J Biol Chem 2000, 275:10745-10753.
89. Metz-Boutigue M.H., Goumon Y., Lugardon K., Strub J.M., Aunis D. Antibacterial peptides are present in chromaffin cell secretory granules. Cell Mol Neurobiol 1998, 18:249-266.
90. Gwadz R.W., Kaslow D., Lee J.Y., Maloy W.L., Zasloff M., Miller L.H. Effects of magainins and cecropins on the sporogonic development of malaria parasites in mosquitoes. Infect Immun 1989, 57:2628-2633.
91. Shahabuddin M., Fields I., Bulet P., Hoffmann J.A., Miller L.H. Plasmodium gallinaceum: differential killing of some mosquito stages of the parasite by insect defensin. Exp Parasitol 1998, 89:103-112.
92. Ghosh J.K., Shaool D., Guillaud P., Ciceron L., Mazier D., Kustanovich I., Shai Y., Mor A. Selective cytotoxicity of dermaseptin S3 toward intraerythrocytic Plasmodium falciparum and the underlying molecular basis. J Biol Chem 1997, 272:31609-31616.
93. Conde R., Zamudio F.Z., Rodriguez M.H., Possani L.D. Scorpine, an anti-malaria and anti-bacterial agent purified from scorpion venom. FEBS Lett 2000, 471:165-168.
94. Akaddar A., Doderer-Lang C., Marzahn M.R., Delalande F., Mousli M., Helle K., Van Dorsselaer A., Aunis D., Dunn B.M., Metz-Boutigue M.H., Candolfi E. Catestatin, an endogenous chromogranin A-derived peptide, inhibits in vitro growth of Plasmodium falciparum. Cell Mol Life Sci 2009, 10.1007/s00018-009-0235-8.
95. Goldberg D.E., Slater A.F., Cerami A., Henderson G.B. Hemoglobin degradation in the malaria parasite Plasmodium falciparum: an ordered process in a unique organelle. Proc Natl Acad Sci U S A 1990, 87:2931-2935.
96. Gaede A.H., Lung M.S., Pilowsky P.M. Catestatin attenuates the effects of intrathecal nicotine and isoproterenol. Brain Res 2009, 1305:86-95.
97. Brutsaert D.L., Fransen P., Andries L.J., De Keulenaer G.W., Sys S.U. Cardiac endothelium and myocardial function. Cardiovasc Res 1998, 38:281-290.
98. Gattuso A., Mazza R., Pellegrino D., Tota B. Endocardial endothelium mediates luminal Ach-NO signaling in isolated frog heart. Am J Physiol 1999, 276:H633-H641.
99. Mazza R., Gattuso A., Mannarino C., Brar B.K., Barbieri S.F., Tota B., Mahata S.K. Catestatin (chromogranin A344-364) is a novel cardiosuppressive agent: inhibition of isoproterenol and endothelin signaling in the frog heart. Am J Physiol Heart Circ Physiol 2008, 295:H113-H122.
100. Aars H. Aortic baroreceptor activity in normal and hypertensive rabbits. Acta Physiol Scand 1968, 72:298-309.
101. West M.J., Korner P.I. The baroreceptor-heart rate reflex in renal hypertension in the rabbit. Clin Exp Pharmacol Physiol 1974, 1:231-239.
102. Bristow J.D., Honour A.J., Pickering G.W., Sleight P., Smyth H.S. Diminished baroreflex sensitivity in high blood pressure. Circulation 1969, 39:48-54.
103. Goldstein D.S. Arterial baroreflex sensitivity, plasma catecholamines, and pressor responsiveness in essential hypertension. Circulation 1983, 68:234-240.
104. Grassi G., Cattaneo B.M., Seravalle G., Lanfranchi A., Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 1998, 31:68-72.
105. Parmer R.J., Cervenka J.H., Stone R.A. Baroreflex sensitivity and heredity in essential hypertension. Circulation 1992, 85:497-503.